Results 261 to 270 of about 1,443,667 (357)

Blocking the CD39/CD73 pathway synergizes with anti-CD20 bispecific antibody in nodal B-cell lymphoma. [PDF]

J Immunother Cancer
Kolbe C, Kauer J, Brinkmann B, Dreger P, Huber W, Müller-Tidow C, Dietrich S, Roider T.   +7 more
europepmc   +1 more source

Biodistribution studies with tumor-targeting bispecific antibodies reveal selective accumulation at the tumor site [PDF]

, 2012
Thomas List, Dario Neri
openalex   +1 more source

Relapsed/Refractory Follicular Lymphoma: Current Advances and Emerging Perspectives

European Journal of Haematology, Volume 114, Issue 5, Page 775-784, May 2025.
ABSTRACT Follicular lymphoma (FL) is a prevalent indolent non‐Hodgkin lymphoma (NHL) characterized by a relapsing course and eventual refractoriness to therapy. Despite advancements in treatment, FL remains incurable, necessitating ongoing research into novel therapeutic strategies.
Giulio Caridà, Enrica Antonia Martino, Antonella Bruzzese, Daniele Caracciolo, Caterina Labanca, Francesco Mendicino, Eugenio Lucia, Virginia Olivito, Teresa Rossi, Antonino Neri, Ernesto Vigna, Pierfrancesco Tassone, Pierosandro Tagliaferri, Fortunato Morabito, Massimo Gentile   +14 more
wiley   +1 more source

A two-column process for bispecific antibody purification based on MabSelect VL resin's strong byproduct removal capability. [PDF]

J Biol Methods
Dong W, Zhang P, Wu D, Wan Y, Li Y.
europepmc   +1 more source

Anti‐CD3 × anti‐GD2 bispecific antibody redirects T‐cell cytolytic activity to neuroblastoma targets [PDF]

, 2012
Maxim Yankelevich, Sri Vidya Kondadasula, Archana Thakur, Steven Buck, Nai‐Kong V. Cheung, Lawrence G. Lum   +5 more
openalex   +1 more source

BAP1 Loss Affords Lipotoxicity Resistance in Uveal Melanoma

Pigment Cell &Melanoma Research, Volume 38, Issue 3, May 2025.
ABSTRACT Uveal melanoma (UM) is an aggressive intraocular malignancy. Despite effective control of primary tumors, ~50% of UM patients develop metastases, with the liver being the predominant secondary site. BAP1 deficiency, present in ~80% of metastatic UM cases, is strongly associated with increased metastatic risk and poor prognosis.
C. J. Cunanan, A. Amirfallah, A. B. Sanders, K. C. Gallant, M. R. Cavallo, E. A. Homer, O. S. El Naggar, J. K. Farnan, G. Romano, J. L. Hope, J. G. Jackson, E. J. Hartsough   +11 more
wiley   +1 more source

Cancer vaccines compensate for the insufficient induction of protective tumor-specific immunity of CD3 bispecific antibody therapy. [PDF]

J Immunother Cancer
Middelburg J, Schaap G, Sluijter M, Lloyd K, Ovcinnikovs V, Schuurman J, van der Burg SH, Kemper K, van Hall T.   +8 more
europepmc   +1 more source

Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas [PDF]

, 2012
Pankaj Gupta, David M. Goldenberg, Edmund A. Rossi, Thomas M. Cardillo, John C. Byrd, Natarajan Muthusamy, Richard R. Furman, Chien‐Hsing Chang   +7 more
openalex   +1 more source

Navigating the Economic Burden of Multiple Myeloma: Insights into Cost-effectiveness of CAR-T and Bispecific Antibody Therapies. [PDF]

Curr Hematol Malig Rep
Keesari PR, Samuels D, Vegivinti CTR, Pulakurthi YS, Kudithi R, Dhar M, Janakiram M.   +6 more
europepmc   +1 more source

Comprehensive Review of Early and Late Toxicities in CAR T-Cell Therapy and Bispecific Antibody Treatments for Hematologic Malignancies. [PDF]

Cancers (Basel)
Bangolo A, Amoozgar B, Mansour C, Zhang L, Gill S, Ip A, Cho C.   +6 more
europepmc   +1 more source